SA¹ú¼Ê´«Ã½

Friday 11 April 2025
Salisbury Foundation Trust

FOI_8388

Internal Reference Number: FOI_8388

Date Request Received: 17/01/2025 00:00:00

Date Request Replied To: 05/02/2025 00:00:00

This response was sent via: By Email

Request Summary: intra-vitreal injections or implants

Request Category: Researcher



 
Question Number 1:
How many of the following intra-vitreal injections/implants has your trust administered in the four-month period from September to December 2024:

• Aflibercept

• Bevacizumab

• Brolucizumab

• Dexamethasone

• Faricimab

• Fluocinolone acetonide

• Ranibizumab - Lucentis

• Ranibizumab - Biosimilar (Ongavia, Ximluci, Byooviz, Rimmyrah)
 
Answer To Question 1:
• Aflibercept 1069

• Bevacizumab 8

• Brolucizumab 0

• Dexamethasone 12

• Faricimab 929

• Fluocinolone acetonide 0

• Ranibizumab - Lucentis 5

• Ranibizumab - Biosimilar (Ongavia, Ximluci, Byooviz, Rimmyrah) 0
 
Question Number 2:
Please see attached
 
Answer To Question 2:
Please see attached.

To accompany this answer to question 2 please also see the documents listed below:

 FOI 8388 - Q2 - intra-vitreal injections or implants -Completed.pdf
Please see Attachments:
 
To return to the list of all the FOI requests please click here

Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.

Person Centred & Safe

Professional

Responsive

Friendly

Progressive

SA¹ú¼Ê´«Ã½, SA¹ú¼Ê´«Ã½ Hospital, Odstock Road, Salisbury, Wiltshire, SP2 8BJ
T: 01722 336262 E: sft.pals@nhs.net
© 2025 SA¹ú¼Ê´«Ã½
Trust Values